Targeting the IGF/PI3K/mTOR pathway and AXL/YAP1/TAZ pathways in primary bone cancer

Danh D. Truong¹, Salah-Eddine Lamhamedi-Cherradi¹, Joseph A. Ludwig *

Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA

ARTICLE INFO
Article history:
Received 3 December 2021
Revised 21 February 2022
Accepted 22 February 2022
Available online 24 February 2022

Keywords:
AXL
Bone cancer
Ewing sarcoma
Osteosarcoma
Chondrosarcoma
IGF-1R
PI3K
mTOR

ABSTRACT
Primary bone cancers (PBC) belong to the family of mesenchymal tumors classified based on their cellular origin, extracellular matrix, genetic regulation, and epigenetic modification. The three major PBC types, Ewing sarcoma, osteosarcoma, and chondrosarcoma, are frequently aggressive tumors, highly metastatic, and typically occur in children and young adults. Despite their distinct origins and pathogenesis, these sarcoma subtypes rely upon common signaling pathways to promote tumor progression, metastasis, and survival. The IGF/PI3K/mTOR and AXL/YAP/TAZ pathways, in particular, have gained significant attention recently given their ties to oncogenesis, cell fate and differentiation, metastasis, and drug resistance. Naturally, these pathways – and their protein constituents – have caught the eye of the pharmaceutical industry, and a wide array of small molecule inhibitors and antibody drug-conjugates have emerged. Here, we review how the IGF/PI3K/mTOR and AXL/YAP/TAZ pathways promote PBC and highlight the drug candidates under clinical trial investigation.

© 2022 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Osteosarcoma (OS) and Ewing sarcoma (ES) are the most frequently occurring malignant primary bone cancers (PBC) of childhood and adolescence [1]. Chondrosarcoma (CS) tends to occur later in the 4th–7th decades. Standard treatment with chemotherapy, radiation, and surgery has variable success across these tumor types, but the cure rate for those with metastatic or relapsed disease has changed little over the last five decades [2].

Fortunately, molecular characterization of these tumors has revealed potential pathways for drug intervention. Though IGF-1 regulates osteogenesis and bone homeostasis in normal bones [3,4], it also instigates an aberrant IGF/PI3K/mTOR pathway signaling cascade in PBC [5]. Downstream of IGF-1R, PI3K activation has been shown in several solid tumors to affect cell metabolism, cell survival, proliferation, and protein synthesis [6,7]. Due to the frequent activation of the IGF/PI3K/mTOR pathway in PBC and other solid tumors, which intersects a range of mechanical and chemical signaling mechanisms in cancer, this pathway has been identified as an attractive target in OS, ES, and CS [8–10]. Though IGF-1R-targeted therapies have been the subject of many clinical trials for sarcoma, with or without mTOR inhibitors [11,12], their impact on cell differentiation, plasticity, and drug resistance mechanisms remain largely unexplored. The high inter-patient heterogeneity among PBC patients also suggests the need for response biomarkers to select and steer patients toward the agents most likely to provide clinical benefit [13,14].

The dysregulated AXL-ABL2-YAP/TAZ feedback loop – comprised of Yes-associated protein 1 (YAP), transcriptional coactivator with PDZ-binding motif (TAZ), and the oncogenic receptor tyrosine kinase (RTK) AXL – have been observed in ES and OS. Activation of YAP, TAZ, and AXL can induce cell proliferation, resistance to biologically targeted therapy, and metastasis of bone sarcoma [7,15–19]. The importance of this pathway in tumorigenesis has naturally led scientists to investigate whether its protein constituents are druggable targets in bone sarcomas [19]. Interestingly, Dupont et al. showed that YAP and TAZ also regulate biomechanical signals independent of the Hippo pathway, which in turn have striking effects on cell fate determination, stem cell properties, and proliferation rates [20]. Colocalization of nuclear YAP and TAZ in mesenchymal stem cells (MSCs) correlates with the environment’s tensegrity. An increased propensity toward osteogenic lineage commitment is induced through high tensegrity. In contrast, less stiff environments favor an adipogenic phenotype and cytosolic YAP/TAZ expression [21]. In human OS cell lines, knockdown of AXL leads to decreased proliferation and increased

¹ Co-first authors.

*Corresponding author.
E-mail address: jaludwig@mdanderson.org (J.A. Ludwig).

https://doi.org/10.1016/j.jbo.2022.100419
2212-1374/© 2022 The Authors. Published by Elsevier GmbH.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
apoptosis[22]. In addition, the clinical activity of cabozantinib, an inhibitor of AXL and other kinases, has been recently reported in phase 2 clinical trials for patients with OS and ES[23].

Though other pathways almost certainly contribute to bone sarcomagenesis, this review focuses exclusively on two important ones, IGF/PI3K/mTOR and AXL/YAP/TAZ, that have immediate clinical relevance given the exponential rise of new investigational agents that have reached the clinic.

2. Clinical description

PBCs are included in the broader category of sarcomas and correspond to 0.2% of diagnosed cancers, which are primarily composed of osteosarcoma (OS), Ewing sarcoma (ES), and chondrosarcoma (CS) [24]. These malignant bone tumors are clinically aggressive and often need extensive multi-modality treatment. Despite their low incidence, PBCs are associated with excessive morbidity and mortality, greatly affecting the children and young adult population[25]. The lack of specific symptoms at disease onset can delay the diagnosis and allow time for local tumor invasion and distant metastasis to bone and lung. Though the 5-year survival rate for those presenting with localized OS and ES reaches 50–70%, only 20–30% of those presenting with lung or bone metastases at diagnosis survive[26]. While slower growing, CS is notoriously resistant to chemotherapy and often recurs locally[27].

2.1. Osteosarcoma

OS is the most common PBC that usually affects children and adolescents[25]. The etiology of OS is complex and may occur due to widespread chromosomal errors or specific gene mutation in p53, RB1, or the RECLQ4 genes that, respectively, cause Li-Fraumeni syndrome, hereditary retinoblastoma, and Rothmund-Thomas syndrome[28]. Interestingly, whole-genome sequencing data suggests that one-third of primary OS – compared with just 2%–3% of other cancer types – have high mutation burdens thought to result from chromothripsis[29]. The phenomenon of chromothripsis (i.e., shattered DNA) occurs when one or more chromosomes are broken into many pieces and then chaotically rejoined[29,30]. Since the resulting DNA damage is unpredictable, one frequently observes marked inter-patient genetic and phenotypic heterogeneity[29,30].

From a clinical perspective, the World health organization classifies OS subtypes by their location relative to the bone cortex and by their grade (high, intermediate, or low). High-grade OS can occur in any bone, but usually it originates near the distal femur (43%) or proximal tibia (23%). These bones experience rapid cell division during the adolescent growth spurt, though it remains to be determined if the stimulatory signals during puberty contribute to tumorigenesis[31]. The main prognostic factor in OS is the presence or absence of metastatic disease. Though beyond the scope of this review, treatment often relies upon chemotherapy (mainly cisplatin, doxorubicin, methotrexate, or ifosfamide) and surgery[28]. Complementing traditional chemotherapy, several molecularly and pathway-targeted therapies have been developed, including immune modulators[32,33], bone signaling regulators, receptor activator of nuclear factor k-B ligand blockade[34,35], and receptor or non-receptor tyrosine kinases inhibitors[14,31,36–37].

2.2. Ewing sarcoma

ES can occur in the bone (mainly in the pelvis, femur, tibia, and ribs) or soft tissue sites (e.g., thoracic wall, gluteal muscle, cervical muscles, and pleura cavities). The cell of origin remains unknown, but many suspect this sarcoma subtype emerges from neural crest cells or mesoderm-derived mesenchymal stem cells[38–40]. Phenotypically, ES is characterized by a small round cell appearance, positive expression of the surface marker CD99[41], and chromosomal translocation of the EWSR1 gene to ETS family genes[42]. This fusion protein acts as an oncogenic transcription factor that controls ES progression. 70–80% of patients with localized ES, and ~30% for those with metastatic disease, survive. All patients receive chemotherapy, which typically consists of vincristine, doxorubicin, cyclophosphamide alternated with ifosfamide and etoposide[38,43]. When practical, surgery is preferred, though unrespectable tumors in the spine or pelvis can successfully be treated with radiation.

Several next-generation EWSR1-FL11 targeted therapeutics are in preclinical development, with at least one compound (TK-216) that has entered phase clinical testing in patients (NCT02657005) [44]. In addition, several other genes were also reported to promote the recurrence and progression of ES, such as VEGF, IGF-1, CAV1, GLI1, RB, and p53, which might be used as therapeutic targets for ES. Several proteins appear to enable resistance to IGF-1R/mTOR-directed treatment, including IRS1, PI3K, STAT3, YAP-1, and TAZ[7].

2.3. Chondrosarcoma

CS is a malignant tumor of bone characterized by cartilage matrix production and a diverse histopathological and clinical behavior[45]. The exact etiology of CS is not known. There may be a genetic or chromosomal component that predisposes certain individuals to this type of PBC. However, the somatic mutations of isocitrate dehydrogenase (IDH) genes that encode for proteins catalyzing the oxidative decarboxylation of isocitrate, producing αKG and CO2 in the Krebs cycle[46,47], are present in 50% of primary conventional CS[48,49]. The CS is subclassified in primary central, secondary peripheral, and periosteal (aka juxtacortical) subtypes[14,50]. The most common primary location is the pelvis, followed by the femur, humerus, and ribs[51]. Conventional CS is a low or intermediate grade (90%), characterized by a slow clinical course and low metastatic potential.

In contrast, the high-grade CS (10%) is associated with high metastatic potential and poor prognosis[48,52]. Among patients with primary CS of bone and metastasis at presentation, low tumor grade, surgical treatment, tumor size <10 cm, and first primary tumor predict prolonged survival[53]. CS is characterized by a resistance to chemo- and radiotherapies mainly due to a high ECM deposition and low neovascularization, which blocks drug diffusion and activity[54]. The IDH1/2 mutations in CS make the development of IDH targeted therapy a promising treatment option, and there are several ongoing clinical trials in Phase I/II assessing the clinical activity of IDH blockades (NCT02273739, NCT02481154/NCT02073994, and NCT02496741).

3. IGF1/PI3K/mTOR pathway

Insulin-like growth factor 1 (IGF-1) is important for several different growth and differentiation processes of normal bone physiology through endocrine mechanisms[55]. IGF-1 receptor (IGF-1R) blockade in chondrocytes, osteoblasts, and osteocytes has shown that IGF-1 signaling is required for controlling cell proliferation and differentiation.

IGF1/PI3K/mTOR pathway activation begins when IGF-1 binds to IGF1R, prompting phosphorylation at several tyrosine residues in the kinase domain (e.g., 1131, 1135, 1136) or membrane domain (e.g., tyrosine 950). IGF-1R phosphorylation, in turn, activates downstream substrates, such as insulin receptor substrate (IRS)
and Shc[56]. IRS1 activates phosphatidylinositol 3 kinase (PI3K) [57] and the extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) network by binding to Shc and Grb2 (Fig. 1) [14,58–59]. PI3K phosphorylates phosphatidylinositol 4,5 bisphosphate, which leads to phosphatidylinositol 3,4,5, trisphosphate. Ultimately, serine/threonine kinase (PDK1) is recruited and AKT is partially activated at threonine-308 (Fig. 1). Full AKT activation is accomplished by Ser-473 phosphorylation by mTORC2 [28,60]. At the terminal end of this cascade, the mammalian target of rapamycin (mTOR) regulates several processes critical for cell proliferation and protein synthesis.

mTOR subsists in two distinct entities, mTORC1 and mTORC2, a serine/threonine tyrosine kinase that regulates normal cell growth, development, metabolism, and angiogenesis. In response to nutrients and growth factor receptor signals, the downstream effectors (p70S6K and 4E-BP1) profoundly affect cellular growth, proliferation, and protein synthesis (translation) [8]. mTORC1 is sensitive to rapamycin and other so-called rapalogs (e.g., temsirolimus, everolimus, ridaforolimus, or rapamycin) [8]. mTORC2, which is not sensitive to rapamycin, can enhance AKT activity [61,62].

The IGF/PI3K/mTOR pathway is linked to the pathogenesis and progression of PBC [63,64]. Comparing PBCs with normal bone cells at the gene expression levels validated a loss of all the intracellular IGF inhibitors, IGFBPs [7,14,65]. This pathway actively modulates cell migration, cell cycle progression, EMT, and tumor growth in preclinical models of PBCs [7,14,65]. Increased IGF1/IGF1R expression has been demonstrated in OS, ES, and CS patients’ tumors, and it was associated with a poor prognosis [14,67–68]. Despite this evidence, IGF-1R blockade in PBC cell lines with mAb against IGF/IGF1R was rarely successful when used as monotherapy [7,69]. Activation of the downstream PI3K/Akt pathway has also been demonstrated in OS and CS cells, though again, single-agent targeting was generally unsuccessful [10,70]. More encouraging results were achieved in combination studies, and partial responses were shown in PBC cases treated with dual IGF1R/mTOR blockade [12,14].

4. Therapeutic opportunities targeting the IGF/PI3K/mTOR pathway in PBC

The IGF/PI3K/mTOR pathway can be therapeutically targeted conceptually at three different levels: 1) blocking its proximal components (either IGF ligands or IGF-1R using antagonistic humanized monoclonal antibodies), 2) impeding its mid constituents at either PI3K or AKT using small molecules tyrosine kinase inhibitors, and 3) blocking its distal mTOR components using rapamycin and its analogs. Given the prominent role this pathway has on vital cellular processes, feedback loops abound and quickly counter the therapeutic effect of most drugs. For that reason, it is increasingly common to see combination strategies employed in the preclinical and clinical setting to block the IGF/PI3K/mTOR pathway at two or more levels in an attempt to mitigate acquired drug resistance [7,14].

4.1. IGF ligand inhibitors

IGF ligand-blockade demonstrated a complementary therapeutic approach that overcame the upregulation of insulin receptors as a mechanism of resistance to IGF-1R neutralization. Humanized monoclonal antibodies against IGF-1 and IGF-2 have been developed by Medimmune (MEDI-573, dusigitumab) and Boehringer Ingelheim (BI836845, xentuzumab). Both antibodies bind and neutralize IGF-1 and IR-α while avoiding unwanted effects upon insulin[71]. These ligand-directed antibodies were generally well tolerated within...
phase 1 trials in patients with solid tumors. To date, the sole clinical experience treating PBC patients with ligand-targeted drugs includes a ES patient who received a subtherapeutic dose of MEKI-573 while enrolled in an early dose cohort[72]. Xentuzumab, which also binds and neutralizes murine IGfs, has shown strong preclinical activity in ES. Despite this, both IGF ligand inhibitors (dusigitumab and xentuzumab) have been discontinued due to poor activity in common cancer types.

4.2. IGF-1R blockade

The IGF-1R pathway has been studied extensively in PBCs [7,65–66]. IGF-1R antagonists have generally consisted of antibodies or small molecule TKIs, as summarized in Table 1 [73–75]. To date, six mAbs had been investigated in clinical trials: R1507 (robaatumumab, Roche), cixutumumab (IMC-A12, ImsClone), SCH-717454 (19D12, Schering-Plough), MK-0646 (dalotuzumab, Merck), AMG479 (Ganitumumab, Amgen), figitumumab (CP-751-871, Pfizer). Single-agent activity ranged between 9 and 14%, and most responses lasted <2 months [73,75–76]. Small molecule IGF-1R antagonists, including NVP-AEW541, BMS-536924, GSX-183870A, and OSI-906 showed promising preclinical activity. However, cross-reactivity to the insulin receptor led to unacceptable toxicity [78–80], and these compounds were subsequently abandoned. Table 2.

4.3. IRS-1 inhibitors

The IGF-1R/PI3K/mTOR pathway has been the target of preclinical studies for OS PBC[87] and has a vital role in various mitogenic and antiapoptotic signaling through other components like insulin receptor substrates 1 and 2 (IRS1/2), which play central roles in cancer cell proliferation, resistance to anticancer drugs, and tumor metastasis[88–90]. A selective inhibitor of IRS1/2, NT157 was evaluated as a dose-dependent inhibitor of growth in several OS cell lines by downregulating the expression of IRS1/2 and principal downstream mediators of the IGF pathway. NT157 affected the OS cell migratory ability. In addition, the same IRS1/2 inhibitor was combined with mTOR and PI3K/mTOR inhibitors, and significant synergistic effects were obtained[87]. This IRS1/2 inhibitor is not yet been tested clinically.

4.4. PI3Ks inhibitors

These targets are downstream of the IGF-1R/IR but also of other RTKs. Their effective targeting can eliminate the activation of downstream signaling, reduce cell proliferation and survival that are induced by other RTKs, and downregulate cell activation caused by PI3K mutations. Impaired PI3K signaling can trigger compensatory alterations at the cellular and whole-body level, the latter occurring via drug-induced hyperglycemia and hyperinsulinemia that activates IR-A[91].

There are two broad types of PI3K inhibitors, the pan-PI3K and the isoform-specific inhibitors. Pan-PI3K inhibitor has been reported to inhibit autophagy and enhance OS cell apoptosis [92,93]. Despite the effective inhibition of the PI3K pathway and PBC tumor growth in PBC preclinical studies, these pan-inhibitors may never be fully developed as clinical therapeutic drugs because of their poor pharmacokinetic parameters, including low solubility, instability, and excessive toxicity. However, the development of isoform-specific inhibitors of PI3K p110 α, β, γ or catalytic subunits have emerged and might offer the opportunity to lower these side effects, thus granting their tolerability. For example, alpelisib, a specific PI3Kα inhibitor that blocks the ATP site, is proposed to reduce cell proliferation and block tumor bone formation in murine preclinical models of OS[94]. Another PI3Kα inhibitor, BKM120, can decrease OS cell invasion and survival[85].

4.5. mTOR inhibitors

As a central hub of cell biology, mTOR profoundly affects whole-organism carbohydrate physiology. mTORC1 and mTORC2 contribute to tumorigenesis differently [99,100] and elicit unique behaviors when targeted. The rapamycin analogs rifadoforlimus, everolimus, and temsirolimus, which inhibit mTORC1, were first approved to treat renal malignancies[101].
A downstream target of the IGF/PI3K/mTOR pathway, activated S6 kinase is readily detectable in PBC specimens. In a subgroup analysis, ridaforolimus led to a non-statistically significant improvement PFS for bone tumors (HR 0.70, 95% CI upper limit >1); this study was not adequately powered for subgroup analyses [102]. Everolimus has demonstrated some activity in osteosarcoma; within a pediatric phase 1 study, one of two enrolled osteosarcoma patients showed prolonged stable disease for several courses[103]. Several drug combinations, rapamycin with cyclophosphamide and temsirolimus with cixutumumab, failed to demonstrate significant activity in OS [12,104]. Ten CS patients were treated with a sirolimus/cyclophosphamide combination, which was well tolerated and had modest clinical activity[105]. Temsirolimus may also potentiate the cytotoxicity of liposomal doxorubicin[106]. Last, neoadjuvant everolimus has been tried in CS (NCT02008019) was suspended due to limited activity.

4.6. Cotargeting IGF/PI3K/mTOR pathway

Given the limited or short-lived antineoplastic response observed when individual proteins are targeted, many have hypothesized that effective blockade of the IGF/PI3K/mTOR will require co-targeting two or more proteins concurrently to avoid counter-productive feedback loop activation. Preclinical data indicate that the combination of mTOR with IGF–1R blockade results in greater Akt downregulation and enhanced antiproliferative effects [7]. This therapeutic approach guided the design of numerous early phase clinical trials assessing mTORC1 and IGF–1R blockade in sarcoma patients [14,107–109]. Dual IGF–1R/mTOR therapies were generally more successful than monotherapy and were reasonably well tolerated compared to traditional cytotoxic chemotherapy [11,14].

While single-agent IGF–1R targeted monoclonal antibodies delivered a clear activity signal, neither the response rate (10–14%) nor response duration (2 months) offers enough clinical benefit to expand into the next clinical trial[75]. During the last decade, our research team has demonstrated that combined IGF–1R/mTOR-targeted therapy was synergistic, with a 29% response rate and, significantly, with a standard response duration enduring more than one year[11]. Later, other trials developed by Schwartz et al. and COG (Children’s Oncology Group) were unsuccessful when trying to replicate these promising results, principally because the mTOR dose was decreased in a sizable fraction for patients due to mucositis or hepatotoxicity [104,110]. Since those studies were conducted, investigators have become adept at palliating mucositis and other mTOR-associated symptoms and thereby have extended the safety profile of mTOR combinations [111,112].

Harmonizing these clinical experiences, our lab and others throughout the country have made considerable advances shaping how to efficiently cotarget the IGF–1/PI3K/mTOR pathway to significantly succeed in managing PBC clinically. Despite exhibiting little single-agent activity, our results suggest mTOR suppression is central to meaningful clinical action. Of critical importance, because mTOR inhibition quickly upregulates IRS–1 and PI3K (due to derepression of the p70S6K → IRS–1 feedback loop) [113–116], it is imperative to simultaneously block the proximal portion of the IGF–1/PI3K/mTOR pathway (Fig. 1).

In our experience, this can be achieved by co-targeting mTOR together with the IGF–1/IGF–2 ligands (plus the hybrid IR–γ/IGF–1R), IGF–1R, or PI3K. As shown in our preclinical studies, IGF–1R targeting in animal models leads to compensatory changes in Smad3, STAT3, and other proteins that can be explored for additional synergy[7]. In the clinic, data from one ES patient who had responded to therapy and then progressed 14 months later on IGF–1R/mTOR-based therapy revealed similar compensatory changes[7]. Preliminary data using alpelisib (a p110α-selective PI3K inhibitor) in ES patient-derived tumor explants (PDX) models suggest a xentuzumab/alpelisib two-drug combination might also be effective. They could serve to expand future clinical trial options if neutralizing antibody programs are revived.

Though antagonists of IGF, IGF–1R, IRS–1, and mTOR have largely been abandoned as a single-agent treatment for PBC, PI3K inhibitors remain under clinical investigation. Alpelisib has been FDA-approved for specific PI3K-mutant breast cancer subtypes. Pan-PI3K inhibitors, such as copanlisib with a broader affinity for the p110α–p110δ catalytic PI3K subunit, have received approval for lymphoma subtypes. To date, PI3K inhibitors have not been studied in PBC. If and when they are, Hopkins et al. have suggested in other cancers that their antineoplastic effect can be magnified by reducing hyperinsulinemia via adherence to a ketogenic diet [117]. Whether that strategy proves beneficial in PBC remains to be determined.

5. AXL-YAP/TAZ positive feedback loop

5.1. The Hippo and YAP/TAZ pathway is conserved across species.

YAP (encoded by Yes-associated protein 1) [118–119] and TAZ (encoded by WWTR1) [118–120] are transcriptional activators that regulate cell proliferation, survival, and differentiation [121,122]. The biological response is directly tied to the location of YAP/TAZ in the cell. For instance, activation leads to the shutting of YAP/TAZ into the nucleus, and suppression of YAP/TAZ maintains its presence in the cytoplasm. When YAP and TAZ were first discovered, the biological function was unclear. Later, key insights regarding YAP and TAZ function were inferred from the effects of Yorkie, a homolog within the Drosophila Hippo signaling pathway[123].

The Hippo signaling pathway is a conserved cascade regulating the growth and size of tissues, involving the translocation of Yorkie, the YAP/TAZ homolog, between the cytoplasm and nucleus. When Hippo signaling is inactivated in Drosophila, it causes enlargement of larval tissue and tumor initiation, indicating the Hippo signaling pathway is a key tumor suppressor[124]. Similar findings emerged in mammalian cells, where YAP/TAZ was shown to regulate organ size[125] and tumor progression. The Hippo signaling pathway is mediated through the kinases MST1/2 and LATS1/2 in mammals. When activated, MST1/2 kinases form a complex with SAV1 to phosphorylate and activate LATS1/2. Subsequently, LATS1/2 phosphorylates YAP and TAZ, marking them for ubiquitination and subsequent degradation[124]. Since the nuclear-localized YAP/TAZ paralogs act as transcription factors, upstream Hippo signaling can inhibit cell proliferation.

Conversely, Hippo inactivation promotes YAP/TAZ nuclear shuttling. Notably, because YAP/TAZ lack DNA-binding domains themselves, they must first complex with one of several TEA-binding domains (TEAD) to exert their diverse epigenetic effects. As discussed shortly, obligate binding to TEAD1 or other TEAD proteins has created a therapeutic opportunity to target TEAD as a potential antineoplastic agent.

5.2. Diverse regulation of YAP/TAZ via mechanotransduction

Though canonical YAP/TAZ activation was first linked to Hippo mutations, Hippo downregulation can have similar effects. Notably, key findings from the regenerative medicine field revealed that YAP/TAZ activity is also critically dependent upon biomechanical cues imparted on cells by their surroundings. In vivo, this mostly occurs through cell-cell adhesion, mediated at the subcellular level by adherens junctions (AJ), and cell-ECM associated focal adhesions (FA) that rely upon integrin/ECM pairings[126]. Besides their
role as structural anchors that preserve tissue shape and polarity. AJ and FA serve as critical macro-molecular hubs that regulate cytoskeletal architecture and recruit signaling proteins. Through both direct and indirect interactions with the Hippo pathway, cytoskeleton, FAK, and cadherin-catenin complexes, YAP/TAZs acts as a cell’s molecular ‘rheostat’ of mechanotransduction.

Cadherin-catenin complexes, FAK-Src kinases, and cytoskeletal tension influence Hippo signaling [127,128]. In normal cells and tissues, cell–cell contact inhibition gradually reduces the rate of proliferation [129]. Cadherins, such as E-cadherin, participate in homophilic binding that initiates a cascade through β-catenin and α-catenin, leading to the interaction with the Merlin and Kirba complex. This complex activates MST1/2 initiating the canonical Hippo signaling. Apical and basolateral cell polarity can regulate the Hippo signaling pathway via AJs, tight junctions (TJ), and gap junctions (GJ) [130]. When correctly engaged, AJs and TJs bind and retain YAP and TAZ at the cell membrane, thereby preventing their activity.

Cell shape and cytoskeletal dynamics also regulate YAP/TAZ [131]. Mechanical cues and activation of RhoA promote increased F-actin polymerization, which inhibits LATS1/2 and activates YAP/TAZ. For example, when cells are placed on larger two-dimensional surfaces or micropatterned culture substrates that promote increased cytoskeletal tension, YAP/TAZ becomes activated. Conversely, rounded cells with low cytoskeletal tension maintain YAP/TAZ within the cytoplasm in an inactive state. This mechanism is influenced by the adhesive area, substrate stiffness, cell density, and shear stress. Taken together, by modulating YAP/TAZ activity, physical cues strongly influence cell proliferation, differentiation, and survival.

5.3. The critical role of YAP/TAZ in connective tissues and PBC

Given the impact of YAP/TAZ and TEAD [118–120] upon stemness [132], cell migration [133], organ size [125], and epithelial-to-mesenchymal transition (EMT) [119], it is not surprising that YAP/TAZ plays a vital role in osteogenesis [134,135] and chondrogenesis [136–138]. Human mesenchymal stem cells (hMSCs), when grown on substrates of varying stiffnesses, adopted distinct cell fates dictated by the specific stiffness. For instance, hMSCs on rigid substrate differentiated toward an osteogenic cell fate while hMSCs on soft substrate differentiated toward an adipocytic cell fate [21].

YAP and TAZ are overexpressed and activated in several cancers and are linked to sustained proliferation, cell survival, EMT [119], and tumor progression. In OS, a recent study showed that 75% of patient histology samples (n = 175) had high YAP expression, with 46% of patients demonstrating YAP nuclear localization [139]. YAP nuclear localization and B1-integrin expression have been linked to adverse metastatic events and worse prognosis [140,141]. Verteporfin, a small molecule TEAD inhibitor, impaired the growth and migration of OS cell lines. ROCK2 silencing in the preclinal setting had a similar effect [139]. While knockdown of YAP in OS cell lines suppressed in vitro tumor cell proliferation, invasion, and tumor formation in mice [142,143], the role of TAZ in these PBCs requires further investigation. To that end, recent work showed that U2OS and HOS human OS cell lines cultured under a migratory ability had increased expression in TAZ and EMT-TFs, including N-cadherin, vimentin, and SNAIL [144]. This EMT-TF phenotypic induction was reversed through inhibition of TAZ [144]. Thus, YAP and TAZ might play divergent roles in OS pathogenesis and progression.

The precise role of YAP and TAZ in ES is less well understood. A recent study comparing YAP expression between ES and normal tissue demonstrated only a moderate increase in ES [145]. Another study found an association of YAP/TAZ expression with disease progression. Knockdown of YAP led to decreased cell proliferation in ES cell lines and decreased tumor growth in an ES xenograft [146]. Further, in ES cell lines, YAP and TAZ regulated the expression of secreted ECM proteins proteoglycan four and tenascin C downstream of CDC42 signaling [147]. Counterintuitively though, in OS, tenasin C complexed to α9β1 integrin to foster metastasis by blocking YAP nuclear translocation and target gene activation [148]. Tenasin C also complexed to α5β1 integrin in ES promoted metastasis by triggering YAP [149] and tyrosine phosphorylation through SRC kinase [150].

Elevated YAP/TAZ expression has been reported in some CS. A recent study showed that less than half of CS specimens harbored activated YAP/TAZ [151]. While little is known of the role of YAP/TAZ in CS, recent studies of chondrogenesis showed that TAZ-deficient mice have impaired chondrogenic differentiation and development [152]. In that regard, the dysregulation of YAP/TAZ may contribute to pathogenesis and aggressiveness in CS [153]. In addition, blockade of the YAP/TAZ-activating kinases SRC and RAC was described to impede chondrosarcoma cells migration [154], and nuclear accumulation of YAP as a consequence of LATS1 inactivation by protein arginine methyltransferase one was shown as the worst prognostic factor in chondrosarcoma [155]. Finally, downregulation of YAP/TAZ and LATS1 in chondrosarcoma cells treated with BRD4 inhibitor, JQ1, led to cell cycle arrest, senescence, and apoptosis [156]. It is likely that the function of YAP/TAZ in the migration or metastasis of bone cancers at least partially recapitulates their role during normal development of the respective tissues of the origin.

5.4. AXL and its impact upon YAP/TAZ

In addition to the YAP/TAZ transcriptional activators, the AXL protein can profoundly affect cell viability, dedifferentiation, cell fate, and metastasis in human bone sarcoma [19,157]. As a TAM (Tyro3, AXL, and MER) RTK family member, AXL also regulates cell survival, proliferation, migration, invasion, and angiogenesis [158–166]. In carcinomas, including hepatocellular carcinoma [167] and lung adenocarcinoma brain metastasis [168], AXL promotes tumorigenesis. In addition to activating YAP/TAZ via AB2L in some cancers, AXL – along with CTGF, CYR61, and MYC1 – is also a downstream YAP/TAZ gene target [169,170]. In lung adenocarcinomas, for instance, YAP was overexpressed and positively correlated with AXL expression [171]. In vitro YAP knockdown significantly reduced AXL expression [171].

6. Therapeutic opportunities targeting AXL, YAP, or TAZ in PBC

Though IGF, PI3K, and mTOR inhibitors have been extensively tested as anticancer agents, drug candidates targeting the AXL/ YAP/TAZ pathway remain in their infancy; see clinical trial data summarized in Table 3. In the preclinical setting, Fleuren et al. showed for the first time that AXL is a potential novel and drug-gable therapeutic target in ES [157]. They demonstrated that AXL and Gas6 are abundantly expressed in ES tumors and that high AXL protein expression is an independent prognostic marker of poor overall survival [157]. They also blocked AXL function using BGB324, which reduced ES cell viability and migration in all cell lines in vitro [157]; however, there have not been any animal preclinical efficacy studies of the AXL inhibitor, BGB324. Preclinical acellularized lung (ACL) models have been used to investigate how these proteins affect OS metastasis [19]. In that system, AXL inhibition attenuated proliferation, migration, and metastatic potential in vitro and in vivo.

In the clinic, the recently opened sarcoma-specific phase 1/2 trial testing BioAtla’s AXL-targeted therapy (NCT03425279) is cur-
rently enrolling patients with ES, OS, CS, and several other sarcoma subtypes. Small molecule oral TEAD inhibitors such as IK-930 are completing IND-enabling studies and are expected to reach the clinic in early 2022. Several multi-targeted FDA-approved TKIs known to antagonize AXL, such as cabozantinib, have shown promising activity in ES and OS (NCT02867592) [23,172–173].

7. Crosstalk between IGF-1R/PI3K/mTOR pathway and AXL/YAP/TAZ positive feedback loop

Our group has previously shown that mechanical stress and culture architecture can affect PBC drug sensitivity in vitro to chemotherapy and IGF-1R/mTOR targeted therapy [175–177]. Increased mechanical stimulation through focal adhesions and actin stress fibers interface with the IGF/PI3K/mTOR pathway and AXL/YAP/TAZ feedback loop in at least two ways. First, FAK activates Akt through the canonical IGF/PI3K/mTOR pathway by stimulating the activity of PI3K [178,179] (Fig. 1). Downstream, Akt then negatively regulates MST1/2, leading to a downregulation of the cytosolic YAP/TAZ and afterward boosted nuclear YAP [180]. Second, a substrate stiffness signal cascade is initiated by Rho GTPases through its interaction with the distal AXL-YAP/TAZ feed-forward loop by suppressing LATS1/2 and directly inhibiting the phosphorylation and subsequent degradation of YAP and TAZ [20,181].

Additional, recent gain-of-function screens identified connections between AXL-YAP/TAZ and the MAPK and PI3K signaling pathways [183]. Further research is needed to determine whether cotargeting the MAPK or PI3K pathways and AXL/YAP/TAZ will prove synergistic as an anticancer strategy for treating patients with high-risk PBCs.

8. Conclusion and future perspectives

Recent research investigating the molecular drivers of PBCs has suggested that the IGF/PI3K/mTOR and AXL/YAP/TAZ pathways are critically important. Nevertheless, despite strong anti-tumor activity in the preclinical setting, anticancer agents directed against IGF-1R or mTOR have had limited clinical utility when used individually. Optimal studies co-targeting the IGF/PI3K/mTOR pathway at two or more levels within the pathway are still being explored to prevent the activation of feedback loops that promote acquired tumor drug resistance. Multi-targeted TKIs with partial AXL activity, like cabozantinib, have demonstrated early success in PBCs, and confirmatory studies are ongoing. However, newer selective inhibitors of AXL, YAP, or TAZ have just reached the clinic, and their effect on PBCs remains to be seen.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

[1] W.I. Wan- Ibrahim, V.A. Singh, O.H. Hashim, P.S. Abdul-Rahman, Biomarkers for Bone Tumors: Discovery from Genomics and Proteomics Studies and Their Challenges, Mol Med 21 (1) (2016) 861–872, https://doi.org/10.2119/molmed.2015.00183.
[2] K.M. Skubitz, D.R. D’Adamo, Sarcoma, Mayo Clin Proc 82 (11) (2007) 1409–1432, https://doi.org/10.4065/82.11.1409.
[3] M. Kawai, C.J. Rosen, The insulin-like growth factor system in bone: basic and clinical implications, Endocrinol Metab Clin North Am 41 (2) (2012) 323–333, https://doi.org/10.1016/j.ecl.2012.04.013.
[4] E.A. Kolb, R. Gorlick, Development of IGF-IR Inhibitors in Pediatric Sarcomas, Current oncology reports 11 (4) (2009) 307–313.
[5] L.J. Helman, P. Melzter, Mechanisms of sarcoma development, Nat Rev Cancer 3 (9) (2003) 685–694, https://doi.org/10.1038/nrc1168.
[6] X. Wan, L.J. Helman, The biology behind mTOR inhibition in sarcoma, Oncologist 12 (8) (2007) 1007–1018, https://doi.org/10.1634/theoncologist.12-8-1007.
[7] Lamhamedi-Cherradi SE, Menegaz BA, Ramamoorthy V, et al. IGF-IR and mTOR Blockade; Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma. Journal of the National Cancer Institute 2016;108(12):1007–1018.
[8] J.A. Ludwig, S.E. Lamhamedi-Cherradi, H.Y. Lee, A. Naing, R. Benjamin, Dual targeting of the insulin-like growth factor and collateral pathways in cancer: combating drug resistance, Cancers (Basel) 3 (3) (2011) 3029–3054, https://doi.org/10.3390/cancers3031029.
[9] R.T. Kurmasheva, L. Dudkin, C. Billsups, L.V. Debelenko, C.L. Morton, P.J. Houghton, The insulin-like growth factor–1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood cancer, Cancer Res 69 (19) (2009) 7662–7671, https://doi.org/10.1158/0008-5472.CAN-09-1693.
[10] Y.-X. Zhang, J.G. van Oosterwijk, E. Sicinska, S. Moss, S.P. Remillard, T. van Wezel, C. Bühnemann, A.B. Hassan, G.D. Demetri, J.V.M.G. Bovée, A.J. Wagner, Functional profiling of receptor tyrosine kinases and downstream signaling in human chondrosarcomas identifies pathways for rational targeted therapy, Clin Cancer Res 19 (14) (2013) 3796–3807, https://doi.org/10.1158/1078-0432.CCR-12-3647.
[11] A. Naing, P. LoRusso, S. Fu, et al., Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing’s sarcoma family tumors. Clin Cancer Res 18 (9) (2012) 2625–2631, https://doi.org/10.1158/1078-0432.CCR-12-0061.
[12] G.K. Schwartz, W.D. Tap, L.X. Qin, et al., Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial, The lancet oncology 14 (4) (2013) 371–382, https://doi.org/10.1016/S1470-2045(13)70049-4.
[13] E.D. Fleuren, Y.M. Versleijen-Jonkers, A.C. van der Luijtgaarden, et al., Predicting IGF-1R therapy response in bone sarcomas; immuno-SPECT imaging with radiolabeled R1507, Clin Cancer Res 17 (24) (2011) 7693–7703, https://doi.org/10.1158/1078-0432.CCR-11-1488.
[14] H.M. Amin, A.C. Morani, N.C. Daw, et al., IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers, Cancers (Basel) 12 (7) (2020), https://doi.org/10.3390/cancers1207168.
[15] A.M. Katschnig, M.O. Kauer, R. Schwentner, et al., EWS-FLI1 perturbs MRTFB/ZASP autoregulatory feedback in Ewing sarcoma, Oncogene 36 (43) (2017) 5995–6005, https://doi.org/10.1038/onc.2017.202.
[16] Ahmed MA, Abedalthagafi M, Anwar AE, Bui MM. Akt and Hippo Pathways in Ewing’s Sarcoma Tumors and Their Prognostic Significance. Journal of Cancer 2015;6(10):1005-1010. (In English). 10.7150/jca.12703.

Table 3
AXL blockade strategies in PBCs.

| AXL Blockade | Name | Company | Sarcoma type | Phase | Clinical Activities |
|--------------|------|---------|--------------|-------|--------------------|
| Antibody-drug Conjugate BA3011 | BioAtla, Inc. | Osteosarcoma Ewing Sarcoma Osteosarcoma Ewing Sarcoma Osteosarcoma Osteosarcoma | I-II | No results. (NCT03425279) ES (26% PR + 49% SD) OS (12% PR + 33% SD) (NCT02243605) No results. (NCT05019703) No results. (NCT04681852) No results. (NCT02867592) |
| TKIs | Cabozantinib | Exelis | Osteosarcoma Ewing Sarcoma Osteosarcoma Osteosarcoma Osteosarcoma | II | No results. (NCT02867592) |
[17] Luu AK, Viloria-Petit AM. Targeting Mechanotransduction in Osteosarcoma: A Comparative Oncology Perspective. International Journal of Molecular Sciences 2020;21(20) (In English). ARTM 7955. 10.3390/ijms21207595
[18] Zhang HT, Gui T, Sang Y, et al. The BET Bromodomain Inhibitor JQ1 Suppresses Chondrosarcoma Cell Growth via Regulation of YAP/t2/Myc Signaling. Journal of Cellular Biochemistry 2017;118(8):2182-2192. (In English). 10.1002/jcb.26583
[19] Lamhamedi-Cherradi SE, Mohiuddin S, Mishra DK, et al. Transcriptional Activities YAP/TAZ and AXL orchestrate dedifferentiation, cell fate, and metastasis in human osteosarcoma. Cancer Gene Therapy 2021 (In English). 10.1038/s11912-021-00611-7
[20] A. Jad, E. Sen, H.L. Sweeney, D.E. Discher, Matrix elasticity directs stem cell lineage specification, Cell 126 (4) (2006) 677–689, https://doi.org/10.1016/j.cell.2006.04.044.
[21] Y. Zhang, Y.J. Tang, Y. Man, F. Pan, Z.H. Li, L.S. Jia, Knockdown of AXL receptor tyrosine kinase in osteosarcoma cells leads to decreased proliferation and increased apoptosis, Int J Immunopathol Pharmacol 26 (1) (2013) 179–188, https://doi.org/10.1177/0377837912460644.
[22] P. Schofield, J.V. Blay, I. Ray-Coquard, Coboazinthumb as an emerging treatment for osteosarcoma, Curr Opin Oncol 32 (4) (2020) 321–331, https://doi.org/10.1097/00001622-202002000-00007.
[23] K.D. Miller, M. Fidler-Benaoudia, T.H. Keegan, H.S. Hipp, A. Jemal, R.L. Siegel, R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, 2020, CA Cancer J Clin 70 (1) https://doi.org/10.3322/caac.21637.
[24] A.J. Engler, S. Sen, H.L. Sweeney, D.E. Discher, Matrix elasticity directs stem cell lineage specification, Cell 126 (4) (2006) 677–689, https://doi.org/10.1016/j.cell.2006.04.044.
[25] D.D. Truong, Salah-Eddine Lamhamedi-Cherradi and J.A. Ludwig Journal of Bone Oncology 33 (2022) 100419.
A.W. Tolcher, J. Sarantopoulos, A. Patnaik, et al., Phase I, pharmacokinetic, and M. von Mehren, C.D. Britten, P. Pieslor, et al., A phase 1, open-label, dose-escalation study of D. Olmos, S. Postel-Vinay, L.R. Molife, et al., Safety, pharmacokinetics, and P. Haluska, M. Menefee, E.R. Plimack, et al., Phase I dose-escalation study of F. Atzori, J. Tabernero, A. Cervantes, et al., A phase I pharmacokinetic and P.M. Anderson, S.S. Bielack, R.G. Gorlick, et al., A phase II study of clinical Z. Duan, E. Choy, D. Harmon, et al., Insulin-like growth factor-I receptor P. Schoffski, D. Adkins, J.Y. Blay, et al., An open-label, phase 2 study evaluating P. Sabbatini, J.L. Rowand, A. Groy, et al., Antitumor activity of GSK1904529A, a M.C. Manara, L. Landuzzi, P. Nanni, et al., Preclinical in vivo study of new P. Haluska, M. Menefee, E.R. Plimack, et al., Phase I dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors, Invest New Drugs 32 (3) (2014) 518–525, https://doi.org/10.1007/s10637-014-0064-y. A.S. Pappo, S.R. Patel, J. Crowley, et al., R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma: results of a phase II Sarcoma Alliance for Research through Collaboration study, J Clin Oncol 29 (34) (2011) 4541–4547, https://doi.org/10.1001/jco.2010.34.0000. A.W. Tolcher, J. Sarantopoulos, A. Patnaik, et al., Phase I, pharmacokinetic, and pharmacodynamic study of AMG 475 as a fully human anti-insulin growth factor receptor antibody in 1. Clin Cancer Res 27 (34) (2009) 3080–3087, https://doi.org/10.1371/journal.pone.0201354. K. Scottlandi, M.C. Manara, G. Niccoliti, et al., Antitumor activity of the insulin-like growth factor receptor kinase inhibitor NVP-AEW541 in murine skeletal tumors, Cancer Res 65 (9) (2005) 3868–3876, https://doi.org/10.1158/0008-5472.CAN-04-3192. M.C. Manara, L. Landuzzi, P. Nanni, et al., Preclinical in vivo study of new insulin-like-growth-factor-1-receptor-specific inhibitor in Ewing’s sarcoma, J Clin Cancer Res 13 (4) (2007) 1322–1330, https://doi.org/10.1158/1078-0432.CCR-06-1518. P. Sabattini, J.L. Rowand, A. Groy, et al., Antitumor activity of GS9194529A, a small-molecule inhibitor of the insulin-like growth factor-1 receptor tyrosine kinase, Clin Cancer Res 15 (9) (2009) 3058–3067, https://doi.org/10.1158/1078-0429.CCR-08-2530. Z. Liu, H. Dai, C. Li, et al., Insulin-like growth factor-1 receptor tyrosine kinase inhibitor cycloglican pimcopedophylbin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines, Mol Cancer Ther 8 (8) (2009) 2122–2130, https://doi.org/10.1158/1535-7163.MCT-09-0115. P.M. Anderson, S.S. Bielack, R.G. Gorlick, et al., Phase II study of cixutumumab in patients with refractory Ewing sarcoma, J Clin Oncol 29 (34) (2011) 4543–4540, https://doi.org/10.1200/JCO.2010.33.0670. S. Chandarlapaty, A. Sawai, M. Scaltriti, et al., AKT inhibition relieves feedback inhibition in combination with cyclophosphamide in the treatment of recurrent or refractory bone and soft tissue sarcoma: a report from the Children’s Oncology Group, Pediatr Blood Cancer 62 (3) (2015) 440–444, https://doi.org/10.1002/10.1002/pbc.25334. R. Bernstein-Molho, Y. Kollender, J. Issakov, et al., Clinical activity of mTOR inhibitor rapamycin in pediatric patients with refractory solid tumors, J Clin Oncol 25 (30) (2007) 4806–4812, https://doi.org/10.1200/JCO.2007.14.47340. F. Conciatori, L. Ciuffreda, C. Bazzichetto, et al., mTOR Cross-Talk in Cancer and Potential for Combination Therapy, Cancers (Basel) 10 (1) (2018), https://doi.org/10.3390/cancers10010023. E. Rad, J.T. Murray, A.R. Tee, Oncogenic Signaling through Mechanistic Target of Rapamycin (mTOR): A Driver of Metabolic Transformation and Cancer Progression, Cancers (Basel) 10 (1) (2018), https://doi.org/10.3390/cancers10010005. O. Abdel-Rahman, M. Fouda, Risk of oral and gastrointestinal mucosal injury in patients treated with erlotinib, temsirolimus or sunitinib: a comparative systematic review and meta-analysis, Expert Rev Anticancer Ther 15 (7) (2015) 847–858, https://doi.org/10.1586/14737472.2015.1047350. G.D. Demetri, S.P. Chawla, I. Ray-Coquard, et al., Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitoridelisib versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy, J Clin Oncol 31 (19) (2013) 2485–2492, https://doi.org/10.1200/JCO.2012.45.9765.
[112] S. Vadhan-Raj, J. Trent, S. Patel, et al., Single-dose palifermin prevents severe
[119] T. Moroishi, C.G. Hansen, K.L. Guan, The emerging roles of YAP and TAZ in
[133] X. Feng, P. Liu, X. Zhou, et al., Thromboxane A2 Activates YAP/TAZ Protein to
[132] T. Kim, S.J. Yang, D. Hwang, et al., A basal-like breast cancer-specific role for
[120] I.M. Moya, G. Halder, Hippo-YAP/TAZ signalling in organ regeneration and
[124] S. Piccolo, S. Dupont, M. Cordenonsi, The biology of YAP/TAZ: hippo signaling
[123] J. Huang, S. Wu, J. Barrera, K. Matthews, D. Pan, The Hippo signaling pathway
[57x649] negative (-) bone and soft tissue sarcomas (STS). American Society of Clinical
[38x705] Texas M. D. Anderson Cancer Center, Houston, TX; Vanderbilt University,
[57x721] University of Michigan, Ann Arbor, MI; H. Lee Moffitt Cancer Canter &
[38x83] [137] H. Goto, M. Nishio, Y. To, et al., Loss of Mob1a/b in mice results in
[38x713] increases bone mass in vivo, PloS one 8 (2) (2013),https://doi.org/10.1371/
[326x713] journal.pone.0056585 e56585.
[326x266] https://doi.org/10.18632/oncotarget.8979.
[326x262] https://doi.org/10.18632/oncotarget.11876.
[326x243] https://doi.org/10.18632/oncotarget.8979.
[326x227] development, Cell Discov 7 (1) (2021) 26,https://doi.org/10.1038/s41421-
[326x187] (2010) 613–618,https://doi.org/10.1016/j.bbrc.2010.05.098.
[326x171] and migratory behaviors of SW1353 chondrosarcoma cells through the
[326x179] H.T. Zhang, T. Gui, Y. Sang, et al., The BET Bromodomain Inhibitor JQ1
[307x610] inhibition of tumor growth and metastatic potential in osteosarcoma cells,
[326x234] M.C. Manara, C. Cristalli, et al., ROCK2 deprivation leads to the
[307x123] S. He, Q. Huang, L. Qin, S. Yang, TAZ is required for chondrogenesis and skeletal
[307x155] W. Xu, Q. Wan, S. Na, H. Yokota, J.L. Yan, K. Hamamura, Suppressed invasive
[326x586] C. Bouvier, N. Macagno, Q. Nguyen, et al., Prognostic value of the Hippo pathway
transcriptional coactivators YAP1/TAZ and beta1-integrin in conventional osteosarcoma, Oncotarget 7 (40) (2016) 64702–64710,
[326x705] journal.pone.0056585 e56585.
[326x713] increases bone mass in vivo, PloS one 8 (2) (2013),https://doi.org/10.1371/
[326x458] promotes epithelial-mesenchymal transition (EMT) and tumorigenesis in
[326x482] of osteosarcoma cells in vitro and in vivo, Oncol Rep 32 (3) (2014) 1265–
[326x625](2016) 2224–2237, https://doi.org/10.1016/j.celrep.2016.02.021.
[326x274] Promote Invadopodia Formation in Ewing Sarcoma, Neoplasia 21 (10)
[326x322] Z. Sun, A. Schwenzer, T. Rupp, et al., Tenascin-C Promotes Tumor Cell
[326x306] the Drosophila Homolog of YAP, Cell 122 (3) (2005) 421–434,https://doi.org/
[326x314] S. He, Q. Huang, L. Qin, S. Yang, TAZ is required for chondrogenesis and skeletal
[326x123] E.D. Fleuren, M.H. Hillebrandt-Roeffen, U.E. Flucke, et al., The role of AXL and
[326x115] H.T. Zhang, T. Gui, Y. Sang, et al., The BET Bromodomain Inhibitor JQ1
[326x131] chondrosarcoma cells, PloS one 9 (11) (2014), https://doi.org/10.1371/
[326x139] alphavbeta3 integrin expression via a c-Src-dependent pathway in human
[326x155] F. Delve, C. Vo, R. Cini, J. Schmidt TD, Kandel RA, YAP/TAZ regulates the expression of proteoglycan 4 and tenasin C in superficial-zone chondrocytes. Eur Cell Mater 2020;39:48-64, 10.22203/eCM.v039a03.
[326x123] H. Goto, M. Nishio, Y. To, et al., Loss of Mob1a/b in mice results in
[307x227] development, Cell Discov 7 (1) (2021) 26,https://doi.org/10.1038/s41421-
[326x219] 021-00254-5.
[326x187] (2010) 613–618,https://doi.org/10.1016/j.bbrc.2010.05.098.
[326x171] and migratory behaviors of SW1353 chondrosarcoma cells through the
[326x179] H.T. Zhang, T. Gui, Y. Sang, et al., The BET Bromodomain Inhibitor JQ1
[326x155] F. Delve, C. Vo, R. Cini, J. Schmidt TD, Kandel RA, YAP/TAZ regulates the expression of proteoglycan 4 and tenasin C in superficial-zone chondrocytes. Eur Cell Mater 2020;39:48-64, 10.22203/eCM.v039a03.
[326x123] H. Goto, M. Nishio, Y. To, et al., Loss of Mob1a/b in mice results in
[307x131] chondrosarcoma cells, PloS one 9 (11) (2014), https://doi.org/10.1371/
[326x139] alphavbeta3 integrin expression via a c-Src-dependent pathway in human
[326x155] F. Delve, C. Vo, R. Cini, J. Schmidt TD, Kandel RA, YAP/TAZ regulates the expression of proteoglycan 4 and tenasin C in superficial-zone chondrocytes. Eur Cell Mater 2020;39:48-64, 10.22203/eCM.v039a03.
[326x123] H. Goto, M. Nishio, Y. To, et al., Loss of Mob1a/b in mice results in
[307x131] chondrosarcoma cells, PloS one 9 (11) (2014), https://doi.org/10.1371/
[326x139] alphavbeta3 integrin expression via a c-Src-dependent pathway in human
[326x155] F. Delve, C. Vo, R. Cini, J. Schmidt TD, Kandel RA, YAP/TAZ regulates the expression of proteoglycan 4 and tenasin C in superficial-zone chondrocytes. Eur Cell Mater 2020;39:48-64, 10.22203/eCM.v039a03.
[326x123] H. Goto, M. Nishio, Y. To, et al., Loss of Mob1a/b in mice results in
[307x131] chondrosarcoma cells, PloS one 9 (11) (2014), https://doi.org/10.1371/
[326x139] alphavbeta3 integrin expression via a c-Src-dependent pathway in human
[326x155] F. Delve, C. Vo, R. Cini, J. Schmidt TD, Kandel RA, YAP/TAZ regulates the expression of proteoglycan 4 and tenasin C in superficial-zone chondrocytes. Eur Cell Mater 2020;39:48-64, 10.22203/eCM.v039a03.
[159] C. Zhu, Y. Wei, X. Wei, AXL receptor tyrosine kinase as a promising anti-cancer approach: mechanisms, functional applications, Mol Cancer 18 (1) (2019) 153, https://doi.org/10.1186/s12943-019-1090-3.

[160] M. Scaltriti, M. Elkabets, J. Baselga, Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy, Clin Cancer Res 22 (9) (2016) 1313–1317, https://doi.org/10.1158/1078-0432.CCR-15-1458.

[161] J. Antony, R.Y. Huang, AXL-Driven EMT State as a Targetable Conduit in Cancer, Cancer Res 77 (14) (2017) 3725–3732, https://doi.org/10.1158/0008-5472.CAN-17-0392.

[162] D.J. Pinato, S. Chowdhury, J. Stebbing, TAMing resistance to multi-targeted kinase inhibitors through Axl and Met inhibition, Oncogene 35 (21) (2016) 2684–2686, https://doi.org/10.1038/onc.2015.374.

[163] M. Schoumancher, M. Burbridge, Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies, Current oncology reports 19 (3) (2017) 19, https://doi.org/10.3892/cor.2017.360.

[164] M.A. Miller, R.J. Sullivan, D.A. Lauffenburger, Molecular Pathways: Receptor Ectodomain Shedding in Treatment, Resistance, and Monitoring of Cancer, Clin Cancer Res 23 (3) (2017) 623–629, https://doi.org/10.1158/1078-0432.CCR-16-0865.

[165] Y.T. Akalu, C.V. Rothlin, S. Ghosh, TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy, Immunol Rev 276 (1) (2017) 165–177, https://doi.org/10.1111/imr.12522.

[166] M.Z. Xu, S.W. Chan, A.M. Liu, et al., AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma, Oncogene 30 (16) (2011) 1229–1240, https://doi.org/10.1038/onc.2010.504.

[167] J.P. Hoj, B. Mayro, A.M. Pendergast, A TAZ-AXL-ABL2 Feed-Forward Signaling Axis Promotes Lung Adenocarcinoma Brain Metastasis, Cell Rep 29 (11) (2019) 3421–3434 e8, https://doi.org/10.1016/j.celrep.2019.09.029.

[168] J. Tumaneng, K. Schlegelmilch, R.C. Russell, et al., YAP mediates crosstalk between the Hippo and PI(3)K-TOR pathways by suppressing PTEN via miR-2684, Mol Cancer 18 (1) (2019) 153, https://doi.org/10.1186/s12943-019-1090-3.

[169] E.R. Molina, L.K. Chim, M.C. Salazar, et al., Mechanically tunable coaxial electropump models of YAP/TAZ mechanoresponsiveness and IGF-1R activation in osteosarcoma, Acta biomaterialia 100 (2019) 38–51, https://doi.org/10.1016/j.actbio.2019.09.029.

[170] C. Zhu, Y. Wei, X. Wei, AXL receptor tyrosine kinase as a promising anti-cancer approach: mechanisms, functional applications, Mol Cancer 18 (1) (2019) 153, https://doi.org/10.1186/s12943-019-1090-3.

[171] A. Italiano, O. Mir, S. Mathoulin-Pelissier, et al., Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial, The lancet oncology 21 (3) (2020) 446–455, https://doi.org/10.1016/S1470-2045(19)30825-3.

[172] A. Italiano, O. Mir, S. Mathoulin-Pelissier, et al., Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial, The lancet oncology 21 (3) (2020) 446–455, https://doi.org/10.1016/S1470-2045(19)30825-3.